Blood test biomarker to help preserve organs in rectal cancer
Part of Cancer, Digestive system clinical trials.
This study looks at a blood test (ctDNA, a way to detect cancer DNA in the bloodstream) to help doctors choose treatment that may spare organs for people with stage II–III rectal cancer. You may be followed to see how well the blood test can guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have confirmed rectal adenocarcinoma that is stage II or III (tumors like T3N0M0 through T4bN2M0)
- Provide written consent before any study-specific tests or procedures
- No signs of spread to distant organs on imaging tests at screening
- No prior treatment for your rectal cancer
- No blood transfusion within 1 month of starting the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is looking at whether a simple blood test (ctDNA monitoring) can help predict how well total neoadjuvant therapy (chemo and radiation before surgery) works for rectal cancer. It may help doctors tailor treatment to your specific needs.
This trial uses a special DNA blood test (circulating tumor DNA) to help guide chemotherapy and radiation before surgery for locally advanced rectal cancer. It aims to improve outcomes by tailoring treatment based on the DNA signals from the tumor.
This study looks at whether a blood test that finds tumor DNA can help doctors choose the best treatment for rectal cancer, possibly allowing some patients to avoid surgery. It tests different chemotherapy and radiation combinations to see if the cancer disappears completely.
This study uses a simple blood test (called MRD) after surgery to see if any tiny bits of cancer DNA are left. It helps doctors decide whether extra chemotherapy is needed or if it can be safely skipped, and it may reduce unnecessary side effects.
This trial uses a simple blood test to look for tiny bits of tumor DNA after colon cancer surgery. If found, it may help doctors catch any remaining cancer early and guide further treatment.
This trial is studying a blood test (CTC) for people with rectal cancer that hasn't spread to other parts of the body. It aims to see how the test relates to treatment outcomes after surgery.
Hear when a new Rectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.